INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)-- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a ...
The published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that ...
TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global ...
Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipam An interim 18-month analysis of an ongoing ...
Q2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues. Our key innovative brands ...
On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy. Q2 2025 shows 10 th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1 ...
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...
In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of ...
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1 If approved, TEV-'749 could help ...
To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the ...
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding ...
Duvakitug (Anti-TL1A) Phase 3 ready; program initiation expected in H2 2025; preparing for olanzapine LAI FDA NDA submission in H2 2025. Transforming Teva: Targeted programs to deliver~$700 million of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results